日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Postoperative adjuvant TACE combined with lenvatinib and immune checkpoint inhibitors for hepatocellular carcinoma with high recurrence risks: a multicenter retrospective study

术后辅助性TACE联合乐伐替尼和免疫检查点抑制剂治疗高复发风险肝细胞癌：一项多中心回顾性研究

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-026-15586-2
Huang, Ziyue; Zhu, Taifeng; Chen, Xiaokun; Piao, Mingjian; Tan, Yang; Li, Chengjie; Liu, Kai; Wang, Shanshan; Zhang, Lei; Du, Shunda; Zhu, Chengpei; Zhou, Kang; Yang, Xiaobo; Zeng, Daobing; Zhao, Haitao
细胞生物学
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2026
文献求助 收藏

Chinese Expert Consensus on the Combination of Targeted Therapy and Immunotherapy with Locoregional Therapy for Intermediate/Advanced Hepatocellular Carcinoma

中国专家共识：靶向治疗联合免疫治疗及局部区域治疗中晚期肝细胞癌

期刊:Liver Cancer
影响因子:9.1
doi:10.1159/000540857
Bi, Xinyu; Lu, Yinying; Chen, Bo; Yang, Zhengqiang; Hong, Zhixian; Wang, Hanping; Sun, Yongkun; Wang, Xiaodong; Yuan, Chunwang; Zeng, Daobing; Huang, Zhen; Zhou, Aiping; Zhang, Wen; Du, Shunda; Zhao, Jianjun; Zhou, Jianguo; Zhai, Yirui; Che, Xu; Zhao, Hong; Zhao, Haitao; Cai, Jianqiang
细胞生物学
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2025
文献求助 收藏

Proteomics and Phosphoproteomics Revealed Dysregulated Kinases and Potential Therapy for Liver Fibrosis.

蛋白质组学和磷酸化蛋白质组学揭示了失调的激酶和肝纤维化的潜在治疗方法

期刊:Molecular & Cellular Proteomics
影响因子:5.5
doi:10.1016/j.mcpro.2025.100991
Cheng Xinyu, Kang Li, Liu Jinfang, Wang Qingye, Zhang Zhenpeng, Zhang Li, Xie Yuping, Chang Lei, Zeng Daobing, Tian Lantian, Zhang Lingqiang, Xu Ping, Li Yanchang
其它
磷酸化
发表日期：2025
文献求助 收藏

Correction: Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer

更正：乐伐替尼联合抗PD-1抗体和吉西他滨化疗作为晚期胆囊癌非一线全身治疗的疗效和安全性

期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-025-03999-0
Tan, Yang; Liu, Kai; Zhu, Chengpei; Wang, Shanshan; Wang, Yunchao; Xue, Jingnan; Ning, Cong; Zhang, Nan; Chao, Jiashuo; Zhang, Longhao; Long, Junyu; Yang, Xiaobo; Zeng, Daobing; Zhao, Lijin; Zhao, Haitao
肿瘤免疫
PD-1
胆囊癌
肿瘤
发表日期：2025
文献求助 收藏

Single-crystalline metal-oxide dielectrics for top-gate 2D transistors

用于顶栅二维晶体管的单晶金属氧化物介质

期刊:Nature
影响因子:48.5
doi:10.1038/s41586-024-07786-2
Zeng, Daobing; Zhang, Ziyang; Xue, Zhongying; Zhang, Miao; Chu, Paul K; Mei, Yongfeng; Tian, Ziao; Di, Zengfeng
发表日期：2024
文献求助 收藏

Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer

乐伐替尼联合抗PD-1抗体和吉西他滨化疗作为晚期胆囊癌非一线全身治疗的疗效和安全性

期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-024-03831-1
Tan, Yang; Liu, Kai; Zhu, Chengpei; Wang, Shanshan; Wang, Yunchao; Xue, Jingnan; Ning, Cong; Zhang, Nan; Chao, Jiashuo; Zhang, Longhao; Long, Junyu; Yang, Xiaobo; Zeng, Daobing; Zhao, Lijin; Zhao, Haitao
肿瘤免疫
PD-1
胆囊癌
肿瘤
发表日期：2024
文献求助 收藏

Effectiveness of Trastuzumab Combined With Capecitabine Treatment in a Patient With Hilar Cholangiocarcinoma Complicated by Liver Metastases With an ERBB2-Activating Mutation: A Case Report

曲妥珠单抗联合卡培他滨治疗伴有肝转移和ERBB2激活突变的肝门部胆管癌患者的疗效：病例报告

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2022.918297
Zeng, Daobing; Zhao, Xiaofei; Di, Liang; Lou, Luyan; Song, Yanfang; Zhang, Yanrui; Liu, Huanhuan; Li, Guangming
胆管癌
ERBB2
肿瘤免疫
肿瘤
发表日期：2022
文献求助 收藏

Metabolic assessment of cerebral palsy with normal clinical MRI using (18)F-FDG PET imaging: A preliminary report

利用 (18)F-FDG PET 成像对临床 MRI 检查正常的脑瘫患者进行代谢评估：初步报告

期刊:Frontiers in Neurology
影响因子:2.8
doi:10.3389/fneur.2022.844911
Wu, Ruimin; Gao, Yan; Zhang, Huaqiong; Chen, Yijia; Tan, Fan; Zeng, Daobing; Wan, Huabing; Yang, Yi; Gu, Jiaowei; Pei, Zhijun
神经科学
代谢
发表日期：2022
文献求助 收藏

Clinical and imaging characteristics of cardiac magnetic resonance presenting with myocardial infarction with non-obstructive coronary arteries in China

中国非阻塞性冠状动脉心肌梗死患者的心脏磁共振临床及影像学特征

期刊:Journal of Cardiothoracic Surgery
影响因子:1.5
doi:10.1186/s13019-022-02072-6
Zhao, Xinxiang; Zeng, Daobing; He, Liping; Sun, Wenjing
心肌梗塞
心血管
发表日期：2022
文献求助 收藏